Untitled

Abstract

Complexation of beta-lap with HPbeta-CD offers a major improvement in drug solubility and bioavailability.

Spectroscopic characterization of the inclusion complexes of luteolin with native and derivatized β-cyclodextrin

“…9,10 The inclusion interaction has been often applied in the improvement of solubility, dissolution rate, bioavailability and chemical stability from oxidation, hydrolysis and photodegradation reaction of drugs. [11][12][13][14] b-Cyclodextrin has been extensively studied despite its low aqueous solubility. With the aim of the functionalities such as better solubility or larger inclusion ability of natural CDs, various CD derivatives such as hydrophilic, hydrophobic, and ionic derivatives have been synthesized.…”

“…These chemically modified CDs have gained importance because of their relatively flexible cavity sizes, greater water solubility or less toxicity. 13,15 As a group, cyclodextrin complexes have been formed with several flavonoids (quercetin, 11 morin, 16 galangin 17 ) improving their solubility and their antioxidant properties. Also, we have determined the thermodynamic parameters which explain the difference in the stability constant (K) obtained.…”

Energetically favorable interactions between diclofenac sodium and cyclodextrin molecules in aqueous media

“…This stimulated a great deal of research toward the synthesis of new host-guest complexes and the structural characterization of the supramolecular adducts in terms of geometry and thermodynamics via a variety of physical methods. Most of the studies found in the literature regarding the CD formulation of drugs, have been carried out from a biomedical standpoint dealing mainly with pharmacokinetic assays, plasma level determinations, in vivo studies [1,9,10,[12][13][14], etc. Few studies [3,6,[15][16][17], however, are involved in physicochemical characteri-* Corresponding author.…”

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone

“…1.6.99.2), a two-electron oxidoreductase (8). The development of novel delivery strategies that increase the bioavailability and tumor targeting of ␤-lap have further served to peak interest in its use as an antitumor agent (9)(10)(11)(12). In fact, ARQ 501 (i.e., ␤-lap) is currently in phase II trials against pancreatic cancers.…”